End Stage Renal Disease Drug Pipeline Analysis Report 2025
Description
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, where kidneys can no longer function effectively, requiring dialysis or a kidney transplant. It accounts for a significant portion of global kidney disease cases, affecting approximately 850 million people worldwide. There is a need for advanced therapies to treat ESRD, as current treatments, such as dialysis, focus on symptom management rather than addressing the root causes. Increasing emphasis on innovative therapeutics, including novel end-stage renal disease drug candidates and advanced biologics, is expected to drive substantial growth in the coming years, enhancing patient outcomes and quality of life.
Report Coverage
The End Stage Renal Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into end stage renal disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for end stage renal disease. The end stage renal disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The end stage renal disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with end stage renal disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to end stage renal disease.
End Stage Renal Disease Drug Pipeline Outlook
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, in which kidneys lose nearly all their function, leading to waste and fluid buildup. It typically occurs due to long-term conditions like diabetes, hypertension, or glomerulonephritis. Without proper treatment, ESRD can be life-threatening as the kidneys can no longer maintain essential bodily functions.
End-stage renal disease (ESRD) treatments focus on replacing lost kidney function. Options include dialysis—hemodialysis or peritoneal dialysis—to remove waste and excess fluid or kidney transplantation for a permanent solution. Managing underlying conditions and lifestyle changes are also crucial. Early diagnosis and treatment improve outcomes and quality of life.
End Stage Renal Disease Epidemiology
End-stage renal disease (ESRD) affects over 2.6 million people globally, with rising incidence, particularly in Asia and the Americas. India reports 1,800 cases per million, with many requiring long-term renal replacement therapy. Hypertensive ESRD constitutes 25% of new cases in the USA, disproportionately impacting Black Americans, Asian Americans, and Alaska Natives.
End Stage Renal Disease – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of end stage renal disease drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total end stage renal disease clinical trials.
End Stage Renal Disease – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the end stage renal disease pipeline analysis include small molecules, biologics, peptides, gene therapies, and cell therapies. The end stage renal disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for end stage renal disease.
End Stage Renal Disease Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the end stage renal disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed end stage renal disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in end stage renal disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for end stage renal disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of end stage renal disease drug candidates.
Drug: Sirolimus
Sirogen, sponsored by Vascular Therapies, is currently being evaluated in the Phase III ACCESS 2 trial to improve arteriovenous (AV) fistula outcomes for hemodialysis patients with kidney disease. This sirolimus-eluting collagen implant delivers sirolimus locally to enhance fistula maturation and reduce failure rates. The study’s primary endpoint is fistula maturation at six months, with results expected by Q2 2025.
Drug: DCR-PHXC
DCR-PHXC, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, is being evaluated in a Phase II open-label study. It is designed to assess its safety and efficacy in patients with Primary Hyperoxaluria Type 1 (PH1) and end-stage renal disease (ESRD), with or without dialysis. This investigational drug targets hepatic oxalate production, aiming to reduce oxalate accumulation and prevent further renal damage.
Drug: AZD4144
AZD4144 is an investigational drug developed by AstraZeneca, currently being evaluated in a Phase I study. It aims to assess its pharmacokinetics, safety, and tolerability in participants with severe renal impairment, including end-stage kidney disease (ESKD), compared to healthy individuals. This open-label, single-dose trial involves multiple cohorts, with findings expected to enhance future ESRD therapeutics and address critical treatment gaps.
Reasons To Buy This Report
The End Stage Renal Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for end stage renal disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into end stage renal disease collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the End Stage Renal Disease – Pipeline Insight Report
Global Chronic Renal Failure Therapeutic Market Report
Renal Anemia Market Report
Renal Anemia Drug Pipeline Analysis
Renal Impairment Drug Pipeline Analysis
Global Clinical Trials Market Report
Report Coverage
The End Stage Renal Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into end stage renal disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for end stage renal disease. The end stage renal disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The end stage renal disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with end stage renal disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to end stage renal disease.
End Stage Renal Disease Drug Pipeline Outlook
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, in which kidneys lose nearly all their function, leading to waste and fluid buildup. It typically occurs due to long-term conditions like diabetes, hypertension, or glomerulonephritis. Without proper treatment, ESRD can be life-threatening as the kidneys can no longer maintain essential bodily functions.
End-stage renal disease (ESRD) treatments focus on replacing lost kidney function. Options include dialysis—hemodialysis or peritoneal dialysis—to remove waste and excess fluid or kidney transplantation for a permanent solution. Managing underlying conditions and lifestyle changes are also crucial. Early diagnosis and treatment improve outcomes and quality of life.
End Stage Renal Disease Epidemiology
End-stage renal disease (ESRD) affects over 2.6 million people globally, with rising incidence, particularly in Asia and the Americas. India reports 1,800 cases per million, with many requiring long-term renal replacement therapy. Hypertensive ESRD constitutes 25% of new cases in the USA, disproportionately impacting Black Americans, Asian Americans, and Alaska Natives.
End Stage Renal Disease – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of end stage renal disease drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Biologics
- Peptides
- Gene Therapies
- Cell Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total end stage renal disease clinical trials.
End Stage Renal Disease – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the end stage renal disease pipeline analysis include small molecules, biologics, peptides, gene therapies, and cell therapies. The end stage renal disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for end stage renal disease.
End Stage Renal Disease Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the end stage renal disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed end stage renal disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in end stage renal disease clinical trials:
- AstraZeneca
- Merck Sharp & Dohme LLC
- Humacyte, Inc.
- Iperboreal Pharma Srl
- Veloxis Pharmaceuticals
- Pathalys Pharma
- Sangamo Therapeutics
- Vascular Therapies, Inc.
- Boehringer Ingelheim
- Gilead Sciences
- Launch Therapeutics
- Parexel
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for end stage renal disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of end stage renal disease drug candidates.
Drug: Sirolimus
Sirogen, sponsored by Vascular Therapies, is currently being evaluated in the Phase III ACCESS 2 trial to improve arteriovenous (AV) fistula outcomes for hemodialysis patients with kidney disease. This sirolimus-eluting collagen implant delivers sirolimus locally to enhance fistula maturation and reduce failure rates. The study’s primary endpoint is fistula maturation at six months, with results expected by Q2 2025.
Drug: DCR-PHXC
DCR-PHXC, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, is being evaluated in a Phase II open-label study. It is designed to assess its safety and efficacy in patients with Primary Hyperoxaluria Type 1 (PH1) and end-stage renal disease (ESRD), with or without dialysis. This investigational drug targets hepatic oxalate production, aiming to reduce oxalate accumulation and prevent further renal damage.
Drug: AZD4144
AZD4144 is an investigational drug developed by AstraZeneca, currently being evaluated in a Phase I study. It aims to assess its pharmacokinetics, safety, and tolerability in participants with severe renal impairment, including end-stage kidney disease (ESKD), compared to healthy individuals. This open-label, single-dose trial involves multiple cohorts, with findings expected to enhance future ESRD therapeutics and address critical treatment gaps.
Reasons To Buy This Report
The End Stage Renal Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for end stage renal disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into end stage renal disease collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the End Stage Renal Disease – Pipeline Insight Report
- Which companies/institutions are leading the end stage renal disease drug development?
- What is the efficacy and safety profile of end stage renal disease pipeline drugs?
- Which company is leading the end stage renal disease pipeline development activities?
- What is the current end stage renal disease commercial assessment?
- What are the opportunities and challenges present in the end stage renal disease drug pipeline landscape?
- What is the efficacy and safety profile of end stage renal disease pipeline drugs?
- Which company is conducting major trials for end stage renal disease drugs?
- Which companies/institutions are involved in end stage renal disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in end stage renal disease?
Global Chronic Renal Failure Therapeutic Market Report
Renal Anemia Market Report
Renal Anemia Drug Pipeline Analysis
Renal Impairment Drug Pipeline Analysis
Global Clinical Trials Market Report
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of End Stage Renal Disease
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: End Stage Renal Disease
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 End Stage Renal Disease: Epidemiology Snapshot
- 5.1 End Stage Renal Disease Incidence by Key Markets
- 5.2 End Stage Renal Disease – Patients Seeking Treatment in Key Markets
- 6 End Stage Renal Disease: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 End Stage Renal Disease: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 End Stage Renal Disease, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of End Stage Renal Disease Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 End Stage Renal Disease Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Sirolimus
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: PLS240
- 10.2.3 Other Drugs
- 11 End Stage Renal Disease Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: DCR-PHXC
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: MK-2060
- 11.2.3 Other Drugs
- 12 End Stage Renal Disease Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: AZD4144
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: MK-5684
- 12.2.3 Other Drugs
- 13 End Stage Renal Disease Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 End Stage Renal Disease, Key Drug Pipeline Companies
- 14.1 AstraZeneca
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Merck Sharp & Dohme LLC
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Humacyte, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Iperboreal Pharma Srl
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Veloxis Pharmaceuticals
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Pathalys Pharma
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Sangamo Therapeutics
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Vascular Therapies, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Boehringer Ingelheim
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Gilead Sciences
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Launch Therapeutics
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Parexel
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
